Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (18)
Paola Rogliani, Josuel Ora, Maria Gabriella Matera, Mario Cazzola & Luigino Calzetta. (2018) The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. Expert Opinion on Drug Safety 17:6, pages 589-596.
Read now
Read now
Santosh Dhungana & Gerard J Criner. (2017) Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 2307-2312.
Read now
Read now
David Price, Anders Østrem, Mike Thomas & Tobias Welte. (2017) Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 141-168.
Read now
Read now
Peter Kardos, Sally Worsley, Dave Singh, Miguel Román-Rodríguez, David E Newby & Hana Müllerová. (2016) Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 2885-2895.
Read now
Read now
Subhabrata Moitra, Arvind B Bhome & Bill B Brashier. (2015) Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date. Drug Design, Development and Therapy 9, pages 1989-1999.
Read now
Read now
Charlotte Suppli Ulrik. (2015) Once-daily glycopyrronium bromide (Seebri Breezhaler®) for the treatment of chronic obstructive pulmonary disease (COPD). Expert Opinion on Pharmacotherapy 16:17, pages 2653-2659.
Read now
Read now
Reynold A Panettieri Jr. (2015) Bronchodilators, receptors and cross-talk: Together is better?. Postgraduate Medicine 127:7, pages 771-780.
Read now
Read now
Morven Wilkie, Simon Finch & Stuart Schembri. (2015) Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease—The Shifting Treatment Paradigm. COPD: Journal of Chronic Obstructive Pulmonary Disease 12:5, pages 582-590.
Read now
Read now
Nanshan Zhong, Changzheng Wang, Xiangdong Zhou, Nuofu Zhang, Michael Humphries, Linda Wang, Chau Thach, Francesco Patalano & Donald Banerji. (2015) LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 1015-1026.
Read now
Read now
Nobuyuki Horita & Takeshi Kaneko. (2015) Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 813-822.
Read now
Read now
Maria Gabriella Matera, Paola Rogliani & Mario Cazzola. (2015) QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 16:7, pages 1079-1090.
Read now
Read now
Charlotte Suppli Ulrik. (2014) Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review. International Journal of Chronic Obstructive Pulmonary Disease 9, pages 331-338.
Read now
Read now
Ruben D Restrepo, Andrew Tate & Joshua Coquat. (2013) Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 14:14, pages 1993-2002.
Read now
Read now
Ronald Dahl, Dalal Jadayel, Vijay KT Alagappan, Hungta Chen & Donald Banerji. (2013) Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. International Journal of Chronic Obstructive Pulmonary Disease 8, pages 501-508.
Read now
Read now
Andrea Rossi & Guido Polese. (2013) Indacaterol: a comprehensive review. International Journal of Chronic Obstructive Pulmonary Disease 8, pages 353-363.
Read now
Read now
Anthony D'Urzo & Claus Vogelmeier. (2012) Future of chronic obstructive pulmonary disease management. Expert Review of Respiratory Medicine 6:3, pages 285-299.
Read now
Read now
Roland Buhl & Donald Banerji. (2012) Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. International Journal of Chronic Obstructive Pulmonary Disease 7, pages 729-741.
Read now
Read now
Charlotte Suppli Ulrik. (2012) Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. International Journal of Chronic Obstructive Pulmonary Disease 7, pages 673-678.
Read now
Read now
Articles from other publishers (29)
Qinxia Zhang, Haifu Zhang, Jianjun Wang, Zhaoyang Ruan, Yifan Dai, Zehai Xia & Qun Lv. (2021) Indacaterol/glycopyrronium affects lung function and cardiovascular events in patients with chronic obstructive pulmonary diseases: A meta-analysis. Heart & Lung 50:4, pages 532-541.
Crossref
Crossref
S. André, B. Conde, E. Fragoso, J.P. Boléo-Tomé, V. Areias & J. Cardoso. (2019) COPD and Cardiovascular Disease. Pulmonology 25:3, pages 168-176.
Crossref
Crossref
Usman Maqsood, Terence N Ho, Karen Palmer, Fiona JR Eccles, Mohammed Munavvar, Ran Wang, Iain Crossingham & David JW Evans. (2019) Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2019:3.
Crossref
Crossref
I. V. Leshchenko. (2018) Fixed dose long-acting bronchodilator combinations in chronic obstructive pulmonary disease: safety, effectiveness and cardiovascular system. Medical Council:15, pages 18-26.
Crossref
Crossref
James F. Donohue, Paul W. Jones, Christian Bartels, Jessica Marvel, Peter D'Andrea, Donald Banerji, David G. Morris, Francesco Patalano & Robert Fogel. (2018) Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. Pulmonary Pharmacology & Therapeutics 49, pages 11-19.
Crossref
Crossref
Dave Singh, Giorgia Ciurlia, Annalisa Piccinno, Annamaria Muraro, Maria Bocchi & Mario Scuri. (2017) Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study. Pulmonary Pharmacology & Therapeutics 42, pages 43-51.
Crossref
Crossref
Kazuhisa Asai, Kazuto Hirata, Shu Hashimoto, Yoshinosuke Fukuchi, Tetsuji Kitawaki, Kimitoshi Ikeda, Robert Fogel & Donald Banerji. (2016) Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: Pooled analysis of SHINE and ARISE. Respiratory Investigation 54:6, pages 428-435.
Crossref
Crossref
Editorial Article. (2016) Therapeutic strategy to prevent acute exacerbations of chronic obstructive pulmonary disease: clinical guidelines of American College of Chest Physicians and Canadian Thoracic Society Guideline (Part 2). PULMONOLOGIYA 26:3, pages 267-291.
Crossref
Crossref
Maria Gabriella Matera, Paola Rogliani, Luigino Calzetta & Mario Cazzola. (2016) Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update. Drug Safety 39:6, pages 501-508.
Crossref
Crossref
Donald A. Mahler, Edward Kerwin, Tim Ayers, Angel FowlerTaylor, Samopriyo Maitra, Chau Thach, Mark Lloyd, Francesco Patalano & Donald Banerji. (2015) FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine 192:9, pages 1068-1079.
Crossref
Crossref
Gerard J. Criner, Jean Bourbeau, Rebecca L. Diekemper, Daniel R. Ouellette, Donna Goodridge, Paul Hernandez, Kristen Curren, Meyer S. Balter, Mohit Bhutani, Pat G. Camp, Bartolome R. Celli, Gail Dechman, Mark T. Dransfield, Stanley B. Fiel, Marilyn G. Foreman, Nicola A. Hanania, Belinda K. Ireland, Nathaniel Marchetti, Darcy D. Marciniuk, Richard A. Mularski, Joseph Ornelas, Jeremy D. Road & Michael K. Stickland. (2015) Prevention of Acute Exacerbations of COPD. Chest 147:4, pages 894-942.
Crossref
Crossref
Erminia Ridolo, Marcello Montagni, Gian Galeazzo Riario-Sforza, Marco Baroni & Cristoforo Incorvaia. (2015) Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety. Therapeutic Advances in Respiratory Disease 9:2, pages 49-55.
Crossref
Crossref
James B Geake, Eli J Dabscheck, Richard Wood-Baker & Christopher J Cates. (2015)
Indacaterol, a once-daily beta
2
-agonist, versus twice-daily beta
2
-agonists or placebo for chronic obstructive pulmonary disease
. Cochrane Database of Systematic Reviews 2017:3.
Crossref
Crossref
Stefano Nardini, Gianna Camiciottoli, Salvatore Locicero, Rosario Maselli, Franco Pasqua, Giovanni Passalacqua, Riccardo Pela, Alberto Pesci, Alfredo Sebastiani & Alessandro Vatrella. (2014) COPD: maximization of bronchodilation. Multidisciplinary Respiratory Medicine 9:1.
Crossref
Crossref
James E. Frampton. (2014) QVA149 (Indacaterol/Glycopyrronium Fixed-Dose Combination): A Review of Its Use in Patients with Chronic Obstructive Pulmonary Disease. Drugs 74:4, pages 465-488.
Crossref
Crossref
Alexander G. Mathioudakis, Victoria Chatzimavridou-Grigoriadou & Georgios A. Mathioudakis. 2014. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
241
256
.
Paul Matthias Diderichsen, Eugène Cox, Steven W. Martin, Adriaan Cleton & Jakob Ribbing. (2013) Predicted heart rate effect of inhaled PF-00610355, a long acting β-adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease. British Journal of Clinical Pharmacology 76:5, pages 752-762.
Crossref
Crossref
J.F. Donohue, M.R. Maleki-Yazdi, S. Kilbride, R. Mehta, C. Kalberg & A. Church. (2013) Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respiratory Medicine 107:10, pages 1538-1546.
Crossref
Crossref
Ronald Dahl, Kenneth R. Chapman, Michael Rudolf, Rajendra Mehta, Pearl Kho, Vijay K.T. Alagappan, Hungta Chen & Donald Banerji. (2013) Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The ENLIGHTEN study. Respiratory Medicine 107:10, pages 1558-1567.
Crossref
Crossref
C. Compton, D. McBryan, E. Bucchioni & F. Patalano. (2013) The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease. Pulmonary Pharmacology & Therapeutics 26:5, pages 562-573.
Crossref
Crossref
Mario Cazzola, Clive Page & Maria Gabriella Matera. (2013) Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulmonary Pharmacology & Therapeutics 26:3, pages 307-317.
Crossref
Crossref
Fa-Ming Jiang, Zong-An Liang, Qiao-Ling Zheng, Rong-Chun Wang, Jian Luo & Chun-Tao Li. (2013) Safety and Efficacy of 12-Week or Longer Indacaterol Treatment in Moderate-to-Severe COPD Patients: A Systematic Review. Lung 191:2, pages 135-146.
Crossref
Crossref
Donald P Tashkin & Gary T Ferguson. (2013) Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respiratory Research 14:1, pages 49.
Crossref
Crossref
Mario Cazzola, Clive P. Page, Luigino Calzetta & M. Gabriella Matera. (2012) Pharmacology and Therapeutics of Bronchodilators. Pharmacological Reviews 64:3, pages 450-504.
Crossref
Crossref
Anders Bjerg, Bo Lundbäck & Jan Lötvall. (2012) The future of combining inhaled drugs for COPD. Current Opinion in Pharmacology 12:3, pages 252-255.
Crossref
Crossref
Thys van der Molen & Mario Cazzola. (2012) Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Primary Care Respiratory Journal 21:1, pages 101-108.
Crossref
Crossref
Peter J BarnesStephanie KornRoland Buhl. 2012. Addressing Unmet Medical Needs in COPD Management. Addressing Unmet Medical Needs in COPD Management
76
87
.
Claus Vogelmeier & Donald Banerji. (2011) NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease 5:3, pages 163-173.
Crossref
Crossref
Mario Cazzola, Luigino Calzetta & Maria Gabriella Matera. (2011) β2-adrenoceptor agonists: current and future direction. British Journal of Pharmacology 163:1, pages 4-17.
Crossref
Crossref